Genta Postscript: Defunct Company’s Former President Charged With Insider Trading
This article was originally published in The Pink Sheet Daily
Executive Summary
Loretta Itri told a longtime friend of the negative results of a Phase III study of Genasense in advanced melanoma before the news was public.
You may also be interested in...
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal
Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.